Amgen, Inc. (AMGN) Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,740 shares of the medical research company’s stock after acquiring an additional 7,293 shares during the period. D.A. Davidson & CO.’s holdings in Amgen were worth $14,562,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Baker Ellis Asset Management LLC acquired a new stake in shares of Amgen during the 3rd quarter worth about $108,000. Phocas Financial Corp. acquired a new stake in shares of Amgen during the 2nd quarter worth about $110,000. Horan Capital Advisors LLC. acquired a new stake in shares of Amgen during the 3rd quarter worth about $150,000. Salem Investment Counselors Inc. raised its position in shares of Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after acquiring an additional 36 shares in the last quarter. Finally, Atlantic Trust LLC acquired a new stake in shares of Amgen during the 2nd quarter worth about $146,000. 79.53% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of AMGN stock opened at $170.48 on Friday. Amgen, Inc. has a twelve month low of $152.16 and a twelve month high of $201.23. The company has a market capitalization of $122,841.41, a price-to-earnings ratio of 13.55, a P/E/G ratio of 2.09 and a beta of 1.37. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. During the same quarter last year, the business posted $2.89 earnings per share. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. equities analysts expect that Amgen, Inc. will post 13.25 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 annualized dividend and a dividend yield of 3.10%. Amgen’s dividend payout ratio (DPR) is currently 41.97%.

Amgen announced that its board has approved a stock repurchase plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Several equities research analysts have recently weighed in on AMGN shares. Argus raised Amgen from a “hold” rating to a “buy” rating and raised their target price for the stock from $192.33 to $220.00 in a research report on Tuesday, January 23rd. Piper Jaffray restated a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Mizuho set a $192.00 price target on Amgen and gave the stock a “buy” rating in a research note on Thursday, December 28th. Goldman Sachs downgraded Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Oppenheimer set a $205.00 price target on Amgen and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $191.26.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 4,575 shares of company stock worth $838,064 over the last quarter. Company insiders own 0.19% of the company’s stock.

WARNING: This article was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.

Leave a Reply